<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310674</url>
  </required_header>
  <id_info>
    <org_study_id>M14P3</org_study_id>
    <secondary_id>Impact N° 926</secondary_id>
    <nct_id>NCT00310674</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age</brief_title>
  <official_title>A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine
      Administered to Healthy Premature and Non Premature Children of 3 months of age
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antibody response, as measured by ELISA, to N. meningitidis serogroup C at one month following three doses of MenC Conjugate Vaccine administered at 3, 5, 11 months of age, together with a hexavalent vaccine.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>antibody response as measured by ELISA at 1 month after second dose of MenC Vaccine and before third dose with hexavalent vaccine</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibody response as measured by BCA in subset of subjects in each group, at 1 month after second dose, immediately before the third and at 1 month following the third dose of MenC Vaccine together with a hexavalent vaccine.</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Prevention of Meningococcal Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal C Conjugate Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children of 11 to 15 weeks of age

        Exclusion Criteria:

          -  Children who previously received any kind of Meningococcal C vaccine, DTaP-IPV-HBV-Hib
             vaccine or a Hepatitis B vaccine at birth

          -  Children who have a previous ascertained or suspected disease caused by N.
             meningitidis, Corynebacterium diphtheriae, Clostridium tetani, poliovirus, Hepatitis B
             or H. influenzae type b, culture proven Bordetella pertussis, or clinical condition of
             spasmodic cough for a period longer than or equal to 2 weeks associated with apnea or
             whooping

          -  Children who have had household contact with and/or intimate exposure to an individual
             with culture proven N. meningitidis serogroup C or Bordetella pertussis, within the
             previous 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Weeks</minimum_age>
    <maximum_age>15 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis - Information Services</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto di Pediatria, Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>March 12, 2007</last_update_submitted>
  <last_update_submitted_qc>March 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2007</last_update_posted>
  <keyword>Prevention of Meningococcal Meningitis</keyword>
  <keyword>meningococcal vaccines</keyword>
  <keyword>conjugate</keyword>
  <keyword>Immunology</keyword>
  <keyword>infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

